Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: Data from the Pfizer International Metabolic Database

European Journal of Endocrinology

Volumn 155, Issue 2, 2006, Pages 253-260

  Maiter, D ^f   Abs, R ^a   Johannsson, G ^b   Scanlon, M ^c   Jonsson P J ^d   Wilton, P ^d   Koltowska Haggstrom M ^d,e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d PFIZER INC   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C;

ADULT; ARTICLE; BODY FAT; BONE MINERAL; CANCER RADIOTHERAPY; CONTROLLED STUDY; CRANIOPHARYNGIOMA; DATA ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHESIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADENOMA; ADULT; CRANIOPHARYNGIOMA; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33747720718     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02209     Document Type: Article

References (29)

1. Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN & Stewart PM. Radiotherapy for non-functioning pituitary tumours. Clinical Endocrinology 1998 48 331-337.
2. Plowman PN. Pituitary adenoma radiotherapy - when, who and how? Clinical Endocrinology 1999 51 265-271.
3. Boelaert K & Gittoes NJ. Radiotherapy for non-functioning pituitary adenomas. European Journal of Endocrinology 2001 144 569-575.
4. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B & Traish D. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. British Medical Journal 1992 304 1343-1346.
5. Peace KA, Orme SM, Sebastian JP, Thompson AR, Barnes S, Ellis A & Belchetz PE. The effect of treatment variables on mood and social adjustment in adult patients with pituitary disease. Clinical Endocrinology 1997 46 445-450.
6. Erfurth EM, Bulow B, Mikoczy Z, Svahn-Tapper G & Hagmar L. Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour? Clinical Endocrinology 2001 55 613-616.
7. Brada M, Ashley S, Ford D, Traish D, Burchell L & Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clinical Endocrinology 2002 57 713-717.
8. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM & Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 1613-1617.
9. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G & Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quarterly Journal of Medicine 1989 70 145-160.
10. Darzy KH & Shalet SM. Pathogenesis and clinical presentation of radiation-induced hypopituitarism. In Central and Peripheral Mechanisms in Pituitary Disease, pp, 51-69. Eds DL Kleinberg & DR Clemmons, Bristol: Bioscientifica, 2002.
11. Shalet SM. Radiation and pituitary dysfunction. New England Journal of Medicine 1993 328 131-133.
12. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395.
13. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P & Wuster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology 1999 50 703-713.
14. Drake WM, Howell SJ, Monson JP & Shalet SM. Optimizing GH therapy in adults and children. Endocrine Reviews 2001 22 425-450.
15. Noad R, Narayanan KR, Howlett T, Lincoln NB & Page RC. Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clinical Oncology 2004 16 233-277.
16. Muller HL, Bruhnken G, Emser A, Faldum A, Etavard-Gorris N, Gebhardt U, Kolb R & Sorensen N. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Child's Nervous System 2005 21 975-980.
17. de Boer H, Blok GJ, Voerman B, de Vries P, Popp-Snijders C & vab der Veen E. The optimal growth hormone replacement dose in adults. derived from bioimpedance analysis. Journal of Clinical Endocrinology and Metabolism 1995 80 2069-2076.
18. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
19. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wiren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
20. Wiren L, Whalley D, Mckenna S & Wilhelmsen L. Application of a disease-specific, quality of life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clinical Endocrinology 2000 52 143-152.
21. Murray RD, Darzy KH, Gleeson HK & Shalet SM. GH-deficient survivors of childhood cancer: GH replacement during adult life. Journal of Clinical Endocrinology and Metabolism 2002 87 129-135.
22. Erfurth EM, Bulow B, Nordstrom CH, Mikoczy Z, Hagmar L & Stromberg U. Doubled mortality rate in irradiated patients reoperated for regrowth of a macroadenoma of the pituitary gland. European Journal of Endocrinology 2004 150 497-502.
23. Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Koltowska-Haggstrom M, Jonsson PJ, Wilton P & Abs R. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2005 90 4636-4643.
24. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ & Shalet SM. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism 2003 88 5865-5870.
25. Page RC, Hammerstey MS, Burke CW & Wass JA. An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clinical Endocrinology 1997 46 401-406.
26. Wallymahmed ME, Foy P & MacFarlane IA. The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects. Clinical Endocrinology 1999 51 333-338.
27. Cuneo RC, Salomon F, Watts GF, Hesp R & Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993 42 1519-1523.
28. Cummings MH, Christ E, Umpleby AM, Albany E, Wierzbicki A, Lumb PJ, Sonksen PH & Russell-Jones DL. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2010-2013.
29. Christ ER, Cummings MH, Jackson N, Stolinski M, Lumb PJ, Wierzbicki AS, Sonksen PH, Russell-Jones DL & Umpleby AM. Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study. Journal of Clinical Endocrinology and Metabolism 2004 89 1801-1807.